Prestin as an Early Biomarker of Hearing Loss in Nasopharyngeal Cancer Patients Undergoing Induction Chemoradiation
<b>Background/Objectives:</b> Nasopharyngeal cancer (NPC) is prevalent in Southeast Asia, Southern China and North Africa. Up to 46% of NPC patients undergoing cisplatin chemoradiation treatment experience irreversible hearing loss. Prestin is a motor protein in the outer hair cells of the cochlea,...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2026-03-01
|
| Col·lecció: | Journal of Otorhinolaryngology, Hearing and Balance Medicine |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2504-463X/7/1/14 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|